Hyperprolactinemia in Children and Adolescents with Use of Risperidone: Clinical and Molecular Genetics Aspects

Journal of Child and Adolescent Psychopharmacology

Volumn 25, Issue 10, 2015, Pages 738-748

  Dos Santos Júnior, Amilton ^a   Henriques, Taciane Barbosa ^a   De Mello, Maricilda Palandi ^a   Neto, Adriana Perez Ferreira ^a   Paes, Lúcia Arisaka ^a   Torre, Osmar Henrique Della ^a   Sewaybricker, Letícia Esposito ^a   Fontana, Thiago Salum ^a   Celeri, Eloisa Helena Rubello Valler ^a   Júnior, Gil Guerra ^a   Dalgalarrondo, Paulo ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2D6; DOPAMINE 2 RECEPTOR; LEPTIN; LEPTIN RECEPTOR; MELANOCORTIN 4 RECEPTOR; PROLACTIN; RISPERIDONE; SCAVENGER RECEPTOR B; SCAVENGER RECEPTOR CLASS B MEMBER 2; SEROTONIN 2C RECEPTOR; UNCLASSIFIED DRUG; NEUROLEPTIC AGENT;

ADOLESCENT; ADOLESCENT DISEASE; ADULT; ALLELE; ARTICLE; BODY MASS; BONE AGE; CHILD; CHILDHOOD DISEASE; CLINICAL EVALUATION; CONTROLLED STUDY; DNA POLYMORPHISM; DRUG USE; FEMALE; HUMAN; HYPERPROLACTINEMIA; MAJOR CLINICAL STUDY; MALE; MOLECULAR GENETICS; MONOTHERAPY; PRESCRIPTION; SINGLE NUCLEOTIDE POLYMORPHISM; SKIN COLOR; TREATMENT DURATION; BLOOD; CHEMICALLY INDUCED; CROSS-SECTIONAL STUDY; GENETIC PREDISPOSITION; GENETICS; NEURODEVELOPMENTAL DISORDERS;

ADOLESCENT; ALLELES; ANTIPSYCHOTIC AGENTS; CHILD; CROSS-SECTIONAL STUDIES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; HYPERPROLACTINEMIA; MALE; NEURODEVELOPMENTAL DISORDERS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROLACTIN; RECEPTOR, SEROTONIN, 5-HT2C; RISPERIDONE;

EID: 84951287759     PISSN: 10445463     EISSN: 15578992     Source Type: Journal    
DOI: 10.1089/cap.2015.0094     Document Type: Article

References (45)

1. Adkins D, Aberg K, McClay J, Bukszár J, Zhao Z, Jia P, Stroup TS, Perkins D, McEvoy JP, Lieberman JA, Sullivan PS, van den Oord EJ: Genomewide pharmacogenomic study of metabolic side effects to antipsychotic drugs. Mol Psychiatry 16:321-332, 2011.
2. Aklillu E, Kalow W, Endrenyi L, Harper P, Miura J, Ozdemir V: CYP2D6 and DRD2 genes differentially impact pharmacodynamic sensitivity and time course of prolactin response to perphenazine. Pharmacogenet Genomics 17:989-993, 2007.
3. Alenius M, Wadelius M, Dahl M-L, Hartvig P, Lindström L, Hammarlund-Udenaes M. Gene polymorphism influencing treatment response in psychotic patients in a naturalistic setting. J Psychiatr Res 42:884-893, 2008.
4. Aman MG, De Smedt G, Derivan A, Lyons B, Findling RL: Double-blind, placebo-controlled study of risperidone for the treatment of disruptive behaviors in children with subaverage intelligence. Am J Psychiatry 159:1337-1346, 2002.
5. Anderson GM, Scahill L, McCracken JT, McDougle CJ, Aman MG, Tierney E, Arnold LE, Martin A, Katsovich L, Posey DJ, Shah B, Vitiello B: Effects of short-and long-term risperidone treatment on prolactin levels in children with autism. Biol Psychiatry 61:545-550, 2007.
6. Besnard I, Auclair V, Callery G, Gabriel-Bordenave C, Roberge C: Antipsychotic-drug-induced hyperprolactinemia: physiopathology, clinical features and guidance [in French]. Encephale 40:86-94, 2014.
7. Cabaleiro T, Ochoa D, López-Rodŕiguez R, Román M, Novalbos J, Ayuso C, Abad-Santos F: Effect of polymorphisms on the phar-macokinetics, pharmacodynamics, and safety of risperidone in healthy volunteers. Hum Psychopharmacol 29:459-469, 2014.
8. Calarge CA, Acion L, Kuperman S, Tansey M, Schlechte JA: Weight gain and metabolic abnormalities during extended risperidone treatment in children and adolescents. J Child Adolesc Psycho-pharmacol 19:101-109, 2009a.
9. Calarge CA, Ellingrod VL, Acion L, Miller DD, Moline J, Tansey MJ, Schlechte JA: Variants of the dopamine D2 receptor and risperidone-induced hyperprolactinemia in children and adolescents. Pharmaco-genet Genomics 19:373-382, 2009b.
10. Calarge CA, Nicol G, Schlechte JA, Burns TL: Cardiometabolic outcomes in children and adolescents following discontinuation of long-term risperidone treatment. J Child Adolesc Psychopharmacol 24:120-129, 2014.
11. Casanueva FF, Molitch ME, Schlechte JA, Abs R, Bonert V, Bron-stein MD, Brue T, Cappabianca P, Colao A, Fahlbusch R, Fideleff H, Hadani M, Kelly P, Kleinberg D, Laws E, Marek J, Scanlon M, Sobrinho LG, Wass JA, Giustina A: Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas. Clin Endocrinol (Oxf) 65:265-273, 2006.
12. Choong E, Polari A, Kamdem RH, Gervasoni N, Spisla C, Jaquenoud Sirot E, Bickel GG, Bondolfi G, Conus P, Eap CB: Pharmacoge-netic study on risperidone long-acting injection: influence of cy-tochrome P450 2D6 and pregnane X receptor on risperidone exposure and drug-induced side-effects. J Clin Psychopharmacol 33:289-98, 2013.
13. Correia CT, Almeida JP, Santos PE, Sequeira AF, Marques CE, Miguel TS, Abreu RL, oliveira GG, Vicente AM: Pharmacogenetics of risperidone therapy in autism: association analysis of eight candidate genes with drug efficacy and adverse drug reactions. Pharmacogenomics J 10:418-430, 2010.
14. Correll CU: Antipsychotic use in children and adolescents: minimizing adverse effects to maximize outcomes. J Am Acad Child Adolesc Psychiatry 47:9-20, 2008.
15. Duval F, Guillon MS, Mokrani MC, Crocq MA, Duarte FG: Relationship between prolactin secretion, and plasma risperidone and 9-hydroxyrisperidone concentrations in adolescents with schizo-phreniform disorder. Psychoneuroendocrinology 33:255-259, 2008.
16. Ercan ES, Basay BK, Basay O, Durak S, Ozbaran B: Risperidone in the treatment of conduct disorder in preschool children without intellectual disability. Child Adolesc Psychiatry Ment Health 5:10, 2011.
17. Farmer CA, Arnold LE, Bukstein OG, Findling RL, Gadow KD, Li X, Butter EM, Aman MG: The treatment of severe child aggression (TOSCA) study: Design challenges. Child Adolesc Psychiatry Ment Health 5:36, 2011.
18. Freeman JB, Choate-Summers ML, Garcia AM, Moore PS, Sapyta JJ, Khanna MS, March JS, Foa EB, Franklin ME: The Pediatric Obsessive-Compulsive Disorder Treatment Study II: Rationale, design and methods. Child Adolesc Psychiatry Ment Health 3:4, 2009.
19. Gonçalves VF, Prosdocimi F, Santos LS, Ortega JM, Pena SDJ: Sex-biased gene flow in African Americans but not in American Caucasians. Genet Mol Res 6:256-261, 2007.
20. Herpertz-Dahlmann B, Bühren K, Remschmidt H: Growing up is hard: Mental disorders in adolescence. Dtsch Arztebl Int 110:432-439, 2013.
21. Ho J, Panagiotopoulos C, McCrindle B, Grisaru S, Pringsheim T: Management recommendations for metabolic complications associated with second generation antipsychotic use in children and youth. J Can Acad Child Adolesc Psychiatry 20:234-241, 2011.
22. Kearns GL, Reed MD: Clinical pharmacokinetics in infants and children. A reappraisal. Clin Pharmacokinet 17 Suppl 1:29-67, 1989.
23. Kleinberg DL, Davis JM, de Coster R, Van Baelen B, Brecher M: Prolactin levels and adverse events in patients treated with risper-idone. J Clin Psychopharmacol 19:57-61, 1999.
24. Knegtering R, Baselmans P, Castelein S, Bosker F, Bruggeman R, van den Bosch RJ: Predominant role of the 9-hydroxy metabolite of risperidone in elevating blood prolactin levels. Am J Psychiatry 162:1010-1012, 2005.
25. La Torre D, Falorni A: Pharmacological causes of hyperprolactine-mia. Ther Clin Risk Manag 3:929-951, 2007.
26. Lencz T, Malhotra AK: Pharmacogenetics of antipsychotic-induced side effects. Dialogues Clin Neurosci 11:405-415, 2009.
27. Lett TA, Wallace TJM, Chowdhury NI, Tiwari AK, Kennedy JL, Müller DJ: Pharmacogenetics of antipsychotic-induced weight gain: review and clinical implications. Mol Psychiatry 17:242-266, 2012.
28. Melis GB, Paoletti AM, Mais V, Mastrapasqua NM, Strigini F, Fruzzetti F, Guarnieri G, Gambacciani M, Fioretti P: The effects of the gabaergic drug, sodium valproate, on prolactin secretion in normal and hyperprolactinemic subjects. J Clin Endocrinol Metab 54:485-489, 1982.
29. Mihara K, Kondo T, Yasui-Furukori N, Suzuki A, Ishida M, Ono S, Kubota T, Iga T, Takarada Y, de Vries R, Kaneko S: Effects of various CYP2D6 genotypes on the steady-state plasma concentrations of risperidone and its active metabolite, 9-hydroxyrisperidone, in Japanese patients with schizophrenia. Ther Drug Monit 25:287-293, 2003.
30. Pandina G, Kushner S, Karcher K, Haas M: An open-label, multi-center evaluation of the long-term safety and efficacy of risperidone in adolescents with schizophrenia. Child Adolesc Psychiatry Ment Health 6:23, 2012.
31. Reis RM, de Angelo AG, Sakamoto AC, Ferriani RA, Lara LAS: Altered sexual and reproductive functions in epileptic men taking carbamazepine. J Sex Med 10:493-499, 2013.
32. Roke Y, van Harten PN, Boot AM, Buitelaar JK: Antipsychotic medication in children and adolescents: A descriptive review of the effects on prolactin level and associated side effects. J Child Adolesc Psychopharmacol 19:403-414, 2009.
33. Roke Y, van Harten PN, Franke B, Galesloot TE, Boot AM, Buitelaar JK: The effect of the Taq1A variant in the dopamine D2 receptor gene and common CYP2D6 alleles on prolactin levels in risperidone-treated boys. Pharmacogenet Genomics 23:487-493, 2013.
34. Saito E, Correll CU, Gallelli K, McMeniman M, Parikh UH, Malhotra AK, Kafantaris V: A prospective study of hyperprolactinemia in children and adolescents treated with atypical antipsychotic agents. J Child Adolesc Psychopharmacol 14:350-358, 2004.
35. Stadler C, Bolten M, Schmeck K: Pharmacotherapeutic intervention in impulsive preschool children: The need for a comprehensive therapeutic approach. Child Adolesc Psychiatry Ment Health 5:11, 2011.
36. Stahl S: The Prescriber'S Guide: Stahl'S Essential Psychopharma-cology, 3rd ed. New York: Cambridge University Press; 2009.
37. Stahl S: Stahl's Essential Psychopharmacology: Neuroscientific Basis and Practical Applications, 3rd ed. New York: Cambridge University Press; 2008.
38. Trenque T, Herlem E, Auriche P, Dramé M: Serotonin reuptake inhibitors and hyperprolactinaemia: A case/non-case study in the French pharmacovigilance database. Drug Saf 34:1161-1166, 2011.
39. Troost PW, Lahuis BE, Hermans MH, Buitelaar JK, van Engeland H, Scahill L, Minderaa RB, Hoekstra PJ: Prolactin release in children treated with risperidone: impact and role of CYP2D6 metabolism. J Clin Psychopharmacol 27:52-57, 2007.
40. Tsigkaropoulou E, Peppa M, Zompola C, Rizos E, Xelioti I, Chat-ziioannou S, Fillippopoulou A, Lykouras L: Hypogonadism due to hyperprolactinemia and subsequent first episode of psychosis. Gend Med 9:56-60, 2012.
41. Van de Kar LD, Javed A, Zhang Y, Serres F, Raap DK, Gray TS: 5-HT2A receptors stimulate ACTH, corticosterone, oxytocin, renin, and prolactin release and activate hypothalamic CRF and oxytocin-expressing cells. J Neurosci 21:3572-3579, 2001.
42. World Health Organization: Growth Reference 5-19 years. 2007. Available at http://www.who.int/growthref/who2007-bmi-for-age/en/index.html
43. Yasui-Furukori N, Saito M, Tsuchimine S, Nakagami T, Sato Y, Sugawara N, Kaneko S: Association between dopamine-related polymorphisms and plasma concentrations of prolactin during ris-peridone treatment in schizophrenic patients. Prog Neuropsycho-pharmacol Biol Psychiatry 32:1491-1495, 2008.
44. Zhang J-P, Malhotra AK: Pharmacogenetics and antipsychotics: Therapeutic efficacy and side effects prediction. Expert Opin Drug Metab Toxicol 7:9-37, 2011.
45. Zito JM, Derivan AT, Kratochvil CJ, Safer DJ, Fegert JM, Greenhill LL: Off-label psychopharmacologic prescribing for children: History supports close clinical monitoring. Child Adolesc Psychiatry Ment Health 2:24, 2008.